Synerkine Pharma is a pharmaceutical company that focuses on developing therapeutics based on research from the Inflammation Research Lab at the University Medical Center Utrecht. The company's research is centered on improving the therapeutic potential of interleukin 10 (IL-10).

Synerkine Pharma

Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.

Thuja Capital

Utrecht Holdings

Flerie Invest

As the race for innovative non-opioid medicines for pain accelerates, we are pleased to announce further progress for our development portfolio of cytokine-cytokine fusion proteins.

Establishing a robust manufacturing process is a crucial step in the development process of every biologic molecule. Today's manufacturing alliance with NorthX Biologics allows us to combine our expertise in cytokine biology with NorthX extensive resources to get our first product candidate to an IND-ready stage. SK-01, which combines the effects of IL-4 and IL-10 as a treatment option for chronic pain, is progressing steadily toward clinical development with complex regional pain syndrome (#CRPS) as the lead indication.

To read the full press release and learn more about Synerkine's cytokine-cytokine fusion strategy, visit https://lnkd.in/dtMt3nPz

#chronicpain #painmedicine #inflammation

Synerkine Pharma appoints industry veteran Anders Ekblom to its Board of Directors. ⬇

We are excited to announce the addition of Anders Ekblom, MD, PhD, DDS, to Synerkine Pharma's Board of Directors. Anders brings a rich set of complementary strengths and expertise to our Board from his positions at AstraZeneca, the Karolinska Institutet, and many more. We are looking forward to working with him as our transformation into a clinical-stage biopharmaceutical company continues.

For more, please visit: https://lnkd.in/dtMt3nPz

Synerkine is entering the next chapter of its corporate development with fresh funds secured and an increasing focus on advancing #Synerkines into the clinic. Read on ⏬ 

Today, we announced an extension of our #SeriesA financing led by Flerie with support from new investors, InnovationQuarter Capital and Utrecht Health Seed Fund, and existing investor Thuja Capital. The equity financing is accompanied by a matching innovation credit from Netherlands Enterprise Agency (RVO). The total new proceeds of EUR 12.1 million will be used to accelerate the development of our lead asset SK-01, a cytokine fusion protein, into clinical studies in complex regional pain syndrome (#CRPS), a severe chronic pain indication.

Read the full press release here: https://lnkd.in/dTzJAAfm

#crpsawareness #chronicpain #venturecapital #IL4 + #IL10

Metric
Company Name	Synerkine Pharma
Symbol
MSH ID	COM:SYNERKINEPHARMA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	NL
Stage
Employee Count	8
Website	synerkinepharma.com
LinkedIn	synerkine-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SYNERKINEPHARMA

Synerkine Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue